PBSC autotransplant for inflammatory bowel disease (IBD): a case of ulcerative colitis

Martí, JL; Mayordomo, J I; Isla, Dolores; Saenz, A.; Escudero, P.; Trés, A.

doi:10.1038/sj.bmt.1703103

Cited by 20 publications

(11 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date, 26 IBD cases consisting of 21 CD and five UC patients who underwent HSCT (eight autologous and 18 allogeneic) for cancer have been reported [8,[10][11][12][13][14][15][16][17][18]. Overall, 24 of 27 (88.9 %) patients have achieved clinical remission in the follow-up periods of 0.5 to 8 years.…”

Section: Hsct and Ibdmentioning

confidence: 99%

Stem cell therapy for inflammatory bowel disease

2015

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) could be curable by ''immune rest'' and correction of the genetic predisposition inherent in allogeneic hematopoietic stem cell transplantation. However, balancing risks against benefits remains challenging. The application of mesenchymal stem cells (MSCs) serving as a site-regulated ''drugstore'' is a recent concept, which suggests the possibility of an alternative treatment for many intractable diseases such as IBD. Depending on the required function of MSC, such as a cell provider, immune moderator, and/or trophic resource, MSC therapy should be optimized to maximize its therapeutic benefit. Therapeutic effects do not always require full engraftment of MSCs. Therefore, optimization of pleiotropic gut trophic factors produced by MSCs, which favoring not only regulating immune responses but also promoting tissue repair, must directly enhance new drug discoveries for treatment of IBD. Stem cell biology holds great promise for a new era of cell-based therapy, sparking considerable interest among scientists, clinicians, and patients. However, the translational arm of stem cell science remains in a relatively primitive state.Although several clinical studies using MSCs have been initiated, early results suggest several inherent problems. In each study, optimization of MSC therapy appears to be the most urgent problem, and can be resolved only by scientifically unveiling the mechanisms of therapeutic action. In the present review, the authors outline how such information would facilitate the critical steps in the paradigm shift from basic research on stem cell biology to clinical practice of regenerative medicine for conquering IBD in the near future.

show abstract

Section: Hsct and Ibdmentioning

confidence: 99%

Stem cell therapy for inflammatory bowel disease

2015

View full text Add to dashboard Cite

show abstract

“…The mechanisms underlying the beneficial effect of HSCT in CD remain unclear. Initially, a beneficial effect is likely to result from eradication Table 1 Relapse at 20 months [24] Soderholm et al remission at 5 years [22] Ditschkowski et al Anumakonda et al www.expert-reviews.com Perspective Stem cell treatment for Crohn's disease of auto reactive T cells and memory cells owing to the direct lymphoablative effects of drugs used in the conditioning regimen; this process is nonspecific and recruitment of inflammatory cells will be restricted for at least 2-3 months until their ablated bone marrow source reconstitutes with cells derived from the graft. Later, there may be an effect of altered immune reconstitution.…”

Section: Perspective Panés Ordás and Ricartmentioning

confidence: 99%

“…Ten patients were in clinical remission following HSCT, with a median follow-up time of 34 months, and the other patients had symptoms of disease but no evidence of lesions at endoscopy. Between 1996 and 2007, seven additional single case reports of patients suffering IBD who underwent HSCT for treatment of cancer were published [18][19][20][21][22][23][24]; five of these had sustained remissions while the other two experienced relapses after 2 and 8 years.…”

Section: Effect Of Hsct Performed For Cancer In Ibdmentioning

confidence: 99%

Stem cell treatment for Crohn’s disease

Panés

Ordás

Ricart

2010

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

While stem cell-based treatments have been established as a clinical standard of care for some conditions, such as hematopoietic stem cell transplants for cancer, the scope of potential stem cell-based therapies has expanded in recent years due to advances in stem cell research, paving the way for the increasing utilization of stem cell therapies in severe immune-mediated diseases including inflammatory bowel diseases (IBDs) and, in particular, Crohn's disease. Both hematopoietic stem cells and mesenchymal (stromal) stem cells are considered to be of potential therapeutic benefit in immune-mediated conditions. A growing body of experimental and clinical evidence shows that hematopoietic stem cell transplant induces long-lasting remission in a majority of patients with active severe Crohn's disease refractory to drug treatments, and the differential effect of potent immunosuppression and immune reconstitution in this setting is under evaluation. Mesenchymal stem cells have been shown to exert immunomodulatory action on various types of immune-mediated diseases, and in experimental models of IBD, but evaluation of the potential efficacy of this therapy in IBD is still in the early stages.

show abstract

“…The committee recommended that autologous hematopoietic stem cell transplantation (HSCT) be preferred to allogeneic HSCT because of the lower risk of severe toxicity (54). Apart from case reports, two series have reported success of autologous HSCT for CD as the primary indication (55,56). All the case reports or series have used high-dose cyclophosphamide with G-CSF for mobilization of HSCs and high-dose cyclophosphamide ± ATG (equine or rabbit) as a preparative regimen with autologous stem cell infusion.…”

Section: Hsc Therapymentioning

confidence: 99%